- Home
- STK vs SGMT Comparison
STK vs SGMT Comparison
Compare STK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | STK | SGMT |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.8M | 676.3M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STK | SGMT |
|---|---|---|
| Price | $54.04 | $9.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $27.55 |
| AVG Volume (30 Days) | 44.5K | ★ 995.7K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.50 | $4.50 |
| 52 Week High | $58.46 | $11.45 |
Technical Indicators
Market Signals| Indicator | STK | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 46.21 |
| Support Level | $50.41 | $6.60 |
| Resistance Level | $55.53 | $11.33 |
| Average True Range (ATR) | 1.08 | 0.69 |
| MACD | 0.05 | -0.19 |
| Stochastic Oscillator | 85.43 | 38.86 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.